Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus.

PubWeight™: 2.01‹?› | Rank: Top 2%

🔗 View Article (PMID 15986345)

Published in Arthritis Rheum on July 01, 2005

Authors

Irene E M Bultink1, Willem F Lems, Piet J Kostense, Ben A C Dijkmans, Alexandre E Voskuyl

Author Affiliations

1: Department of Rheumatology, VU University Medical Center, Slotervaart Hospital, and Jan van Breemen Institute, Amsterdam, The Netherlands. iem_bultink@hotmail.com

Articles citing this

Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis (2007) 2.34

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69

The socioeconomic burden of SLE. Nat Rev Rheumatol (2009) 1.42

Osteoporosis, inflammation and ageing. Immun Ageing (2005) 1.40

Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int (2008) 1.39

T cell replicative senescence in human aging. Curr Pharm Des (2013) 1.31

Erosive arthritis. Arthritis Res Ther (2007) 1.11

Clinical relevance of vertebral fractures. Ann Rheum Dis (2007) 0.92

Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int (2010) 0.91

Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int (2012) 0.90

The anti-inflammatory role of vitamin e in prevention of osteoporosis. Adv Pharmacol Sci (2011) 0.89

Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol (2009) 0.87

Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) (2010) 0.87

Bone effects of biologic drugs in rheumatoid arthritis. Clin Dev Immunol (2013) 0.86

Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep (2012) 0.85

Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res (Hoboken) (2010) 0.85

Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. Osteoporos Int (2012) 0.84

Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. Rheumatology (Oxford) (2013) 0.84

Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int (2013) 0.84

Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol (2008) 0.83

RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int (2015) 0.83

Prevalence and risk factors of vertebral compression fractures in female SLE patients. Arthritis Res Ther (2010) 0.83

Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med (2012) 0.82

Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle (2015) 0.81

The anti-inflammatory effect of Z-Ligustilide in experimental ovariectomized osteopenic rats. Inflammation (2012) 0.81

Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int (2012) 0.81

Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) (2010) 0.80

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther (2010) 0.80

Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus. Osteoporos Int (2015) 0.79

Locally measured microstructural parameters are better associated with vertebral strength than whole bone density. Osteoporos Int (2013) 0.78

Role of Fas and Treg cells in fracture healing as characterized in the fas-deficient (lpr) mouse model of lupus. J Bone Miner Res (2014) 0.78

Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation. Clin Rheumatol (2015) 0.78

Usefulness of ceruloplasmin testing as a screening methodology for geriatric patients with osteoporosis. J Phys Ther Sci (2016) 0.77

Vitamin D supplementation in the pediatric rheumatology clinic. Curr Rheumatol Rep (2011) 0.77

Immune modulation as a therapeutic strategy in bone regeneration. J Exp Orthop (2015) 0.77

Prevalence and possible risk factors of low bone mineral density in untreated female patients with systemic lupus erythematosus. Biomed Res Int (2015) 0.77

Sex-related differences in the association between waist circumference and bone mineral density in a Korean population. BMC Musculoskelet Disord (2014) 0.76

Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis. Medicine (Baltimore) (2017) 0.75

Bone disease in newly diagnosed lupus nephritis patients. PLoS One (2014) 0.75

Systemic lupus erythematosus and fractures. RMD Open (2015) 0.75

Current and emerging treatment options in the management of lupus. Immunotargets Ther (2016) 0.75

A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology. Open Access Rheumatol (2012) 0.75

Vitamin D Status in Patients with Systemic Lupus Erythematosus in Serbia: Correlation with Disease Activity and Clinical Manifestations. Open Access Maced J Med Sci (2015) 0.75

Inter-daily variability in body composition among young men. J Physiol Anthropol (2015) 0.75

Low bone density and vertebral fractures in systemic lupus erythematosus: comment on the article by Bultink et al. Arthritis Rheum (2006) 0.75

Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy. BMC Musculoskelet Disord (2015) 0.75

Vitamin D status in Egyptian patients with juvenile-onset systemic lupus erythematosus. Rheumatol Int (2015) 0.75

Prevalence and predictors of vitamin D insufficiency in supplemented and non-supplemented women with systemic lupus erythematosus in the Mediterranean region. Rheumatol Int (2016) 0.75

Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases. J Ginseng Res (2016) 0.75

Cortical thinning and progressive cortical porosity in female patients with systemic lupus erythematosus on long-term glucocorticoids: a 2-year case-control study. Osteoporos Int (2015) 0.75

Inflammatory diseases and bone fragility. Osteoporos Int (2017) 0.75

[Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines]. Wien Klin Wochenschr (2011) 0.75

Articles by these authors

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79

Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum (2004) 7.13

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57

Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med (2007) 5.05

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73

Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr (2003) 2.70

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67

Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55

A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care (2002) 2.51

Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol (2002) 2.42

Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation (2003) 2.28

Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum (2009) 2.24

Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int (2002) 2.18

Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis (2011) 2.11

Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. Eur Heart J (2003) 2.03

Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum (2006) 2.00

Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension (2003) 2.00

Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest (2005) 1.97

Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum (2004) 1.94

Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum (2003) 1.92

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis (2010) 1.81

Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80

Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum (2006) 1.79

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78

Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care (2009) 1.77

Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77

Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis (2007) 1.77

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol (2008) 1.75

The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum (2011) 1.63

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62

Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med (2015) 1.58

Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol (2007) 1.58

A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. Rheumatology (Oxford) (2011) 1.57

Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis (2007) 1.55

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Ann Intern Med (2016) 1.51

The influence of chronic diabetes mellitus on the thickness and the shape of the anterior and posterior surface of the cornea. Cornea (2007) 1.48

Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2009) 1.47

Avoidance of activities in early symptomatic knee osteoarthritis: results from the CHECK cohort. Ann Behav Med (2012) 1.46

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. Arthritis Rheum (2010) 1.45

Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol (2012) 1.42

Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol (2003) 1.41

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis (2011) 1.40

Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study. J Rheumatol (2012) 1.40

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol (2003) 1.39

Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum (2011) 1.39

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis (2007) 1.37

Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care (2003) 1.36

The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis (2010) 1.31

Active involvement of alarmins S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum (2012) 1.30

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29

Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. J Rheumatol (2002) 1.29

Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum (2003) 1.28

Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum (2010) 1.28

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum (2010) 1.27

High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol (2008) 1.24

A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet (2011) 1.24

Improved glycaemic control in type 1 diabetes patients following participation per se in a clinical trial--mechanisms and implications. Diabetes Metab Res Rev (2003) 1.22

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol (2005) 1.22

Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology (2002) 1.20

Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum (2009) 1.19

Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol (2006) 1.17

Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum Mol Genet (2012) 1.17

Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis (2004) 1.15

Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs (2005) 1.14

18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med (2010) 1.13

The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab (2004) 1.12

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum (2013) 1.12